Stevanato Group S.p.A.

Good afternoon. This is the Corvus Call Conference Operator. Welcome and thank you for joining the Stevanato Group Second Quarter 2023 Financial Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead, Madam.

Good morning, and thank you for joining us. With me today is Franco Stevinato, Executive Chairman, Franco Moro, Chief Executive Officer, and Marco De Lago, Chief Financial Officer. A presentation illustrating today's results can be found on the IR section of our website. Some statements being made today will be forward-looking in nature and are only predictions. Actual events and results may differ materially as a result of risks we face, including those discussed in item 3D entitled Risk Factors in the company's most recent annual report on Form 20F filed with the SEC. We encourage you to review the information contained in our earnings release in conjunction with our SEC filings and our latest Form 20F. The company does not assume any obligation to revise or update these forward-looking statements to reflect subsequent events or circumstances, except as required by law. Today's presentation may contain non-GAAP financial information. Management uses this information in its internal analyses of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. For a reconciliation of the non-GAAP measures, please see the company's most recent earnings press release. And now, I hand the call over to Franco Stevinato for opening remarks.

Thank you, Lisa. We are pleased with another quarter of solid operational and financial performance as we continue to build on our track record and execute against our objectives. We are making progress on all fronts, as evidenced in today's results. we continue to achieve our near-term growth target of high single digit to low double digit growth. We are successfully responding to market demand, which in turn is driving our mix shift towards high value solutions. This keeps us on track to achieve our mid-term target for revenue from high value solution in the high 30% range in 2026. Our investment in growth platforms are currently going as planned as we expand capacity for high-value solutions to satisfy strong customer demand in key end markets like biologics. And lastly, we are benefiting from growth in biologics, which has a projected compounded annual growth rate of approximately 15% through 2027 and is currently our fastest growing end market. Our differentiated easy-fill products are ideally suited to meet the mission-critical needs of biologics, and our pipeline of projects is heavily weighted towards this market. Over the last several years, we have laid the foundation to drive sustainable, long-term organic growth, and we believe we are well positioned to capitalize on the many secular tailwinds as we continue to create and drive shorter value. Thank you. I will now hand the call over to Franco.